The latter clinical observation may also be attributed to the different effect profile of Gla-300 vs. Gla-100, which addresses control of glucose production more effectively without promoting glucose utilization owing to less fluctuation in insulin concentration, therefore allowing higher dosing without prompting hypoglycemia [27]. This evidence concerns the gene INS and Hypoglycemia.